Neurology

FDA Panel Fails to Support Novel Opioid for Depression



An FDA advisory panel failed to endorse the approval of a novel opioid to treat major depressive disorder because of insufficient efficacy data.
News Alerts

Source link

Related posts

Efficacy of Raltegravir in Preventing Progression of Relapsing Remitting MS

Newsemia

UF Health named Parkinson’s Research Center of Excellence

Newsemia

A dozen years of evolution of neurology clerkships in the United States: Looking up

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World